Literature DB >> 10623813

Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method.

A Chen1, G Zheng, M L Tykocinski.   

Abstract

Activation of T cells is dependent upon coordinate engagement of Ag and costimulator receptors on their surfaces. In the case of the Ag receptors (TCRs), activation thresholds have been defined, with the number of TCRs that must be triggered to stimulate cytokine secretion by individual activated T cells differing for the various cytokines. In the present study, we have determined whether comparable activation thresholds exist for the costimulator receptors on T cells. To facilitate this type of quantitative costimulator analysis, we developed a novel two-step protein transfer approach that permits delivery of graded amounts of proteins to APC surfaces. By adding a human B7-1. Fcgamma1 (Fc domain of human IgG1) fusion protein to cells precoated with palmitated protein A, fine titration of the B7-1 extracellular domain was achieved. The B7-1. Fcgamma1 reincorporated into cell membranes by this method retained costimulator function, as measured by an in vitro proliferation assay. The degree of proliferation was dependent on the surface density of B7-1. Fcgamma1. Significantly, the threshold B7-1. Fcgamma1 density required for cytokine production differed between IFN-gamma and IL-2 and mirrored the hierarchy (IFN-gamma < IL-2) described previously for the TCR activation threshold. Hence, this study invokes a novel protein transfer strategy to establish that the levels of surface costimulator on APCs can dictate both the magnitude and the quality of evoked T cell responses. The notion of costimulator receptor activation thresholds emerges.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623813     DOI: 10.4049/jimmunol.164.2.705

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Synthetic cell surface receptors for delivery of therapeutics and probes.

Authors:  David Hymel; Blake R Peterson
Journal:  Adv Drug Deliv Rev       Date:  2012-02-25       Impact factor: 15.470

2.  A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.

Authors:  Ledia Goga; Sathnur B Pushpakumar; Gustavo Perez-Abadia; Paul Olson; Gary Anderson; Chirag V Soni; John H Barker; Claudio Maldonado
Journal:  J Surg Res       Date:  2010-10-16       Impact factor: 2.192

Review 3.  Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery.

Authors:  Susheel Kumar Nethi; Shubhmita Bhatnagar; Swayam Prabha
Journal:  AAPS PharmSciTech       Date:  2021-03-08       Impact factor: 3.246

Review 4.  Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

Authors:  Ann De Becker; Ivan Van Riet
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 5.  Strategies for cell membrane functionalization.

Authors:  James Pk Armstrong; Adam W Perriman
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 6.  Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.

Authors:  Peter Y Li; Zhiyuan Fan; Hao Cheng
Journal:  Bioconjug Chem       Date:  2018-01-11       Impact factor: 4.774

7.  Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.

Authors:  Ledia Goga; Gustavo Perez-Abadia; Sathnur B Pushpakumar; Daniel Cramer; Jun Yan; Nathan Todnem; Gary Anderson; Chirag Soni; John Barker; Claudio Maldonado
Journal:  Open Cardiovasc Med J       Date:  2010-07-20

Review 8.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Targeting mesenchymal stem cells to activated endothelial cells.

Authors:  In Kap Ko; Thomas J Kean; James E Dennis
Journal:  Biomaterials       Date:  2009-04-17       Impact factor: 12.479

Review 10.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.